When the flu hits, it can feel like an unstoppable force: soaring fever, relentless cough, congested nose, and a throat that feels like sandpaper. For many, Tamiflu is the go-to solution—a prescription antiviral that’s widely recognized for treating and even preventing the illness. But here’s the surprising part: Tamiflu isn’t the only game in town. There’s a whole world of flu treatments out there that often go unnoticed, and they could be just what you need for relief.
While Tamiflu is a household name, other antiviral medications are quietly making their mark in the United States. Some of these alternatives are tailored for specific groups, which is why they might not get as much attention (https://www.cdc.gov/flu/treatment/antiviral-drugs.html). Take Xofluza, for example—a single-dose pill approved for anyone aged 5 and older. It’s a strong contender for those who might otherwise be prescribed Tamiflu, offering a simpler, sometimes more effective option.
But here’s where it gets controversial: While Tamiflu has been the go-to for years, Xofluza is gaining traction—but not without debate. Some experts worry about the influenza virus developing resistance to Xofluza, especially in younger children. Dr. William Schaffner, an infectious disease expert, notes that resistance occurs in about 10% of cases, which isn’t insignificant. This has kept Tamiflu in the lead for many practitioners, despite its longer treatment duration and side effects like nausea and vomiting.
Antiviral medications work best when started within two days of symptoms, so knowing your options is crucial. The CDC recommends four antiviral drugs for this flu season: Tamiflu (oseltamivir), Xofluza (baloxavir), Relenza (zanamivir), and Rapivab (peramivir) (https://www.cdc.gov/flu/treatment/antiviral-drugs.html). Each has its pros and cons, and the right choice depends on factors like age, severity of symptoms, and even cost.
Tamiflu, for instance, is approved for treating flu in people as young as 2 weeks old and preventing it in those 1 year and older. It’s available in liquid or capsule form and typically requires twice-daily doses for five days. Generic versions can cost around $50 or less without insurance (https://www.goodrx.com/tamiflu?c), but side effects like nausea and vomiting are common. And this is the part most people miss: Studies show that about 18% of people experience vomiting with Tamiflu, compared to just 5% with Xofluza (https://pmc.ncbi.nlm.nih.gov/articles/PMC10569673/).
Xofluza, on the other hand, is a one-and-done deal—a single tablet for those aged 5 and older. It can treat or prevent the flu but comes with a higher price tag of nearly $200 without insurance (https://www.goodrx.com/xofluza?srsltid=AfmBOorpfTCHg0ZxUo26czQwzVfqtltq-qeYhS72mql5MTa4BrGHdob4). Coupons can help offset the cost (https://www.xofluza.com/save-on-xofluza/coupon.html), and side effects like diarrhea are less common than vomiting. Dr. Ari Brown, a Texas-based pediatrician, notes that Xofluza stops viral shedding in just one day, compared to three days for Tamiflu. This means less exposure for your household and potentially fewer people getting sick.
Rapivab is another option, approved for ages 6 months and older. It’s administered as a single intravenous infusion by a healthcare provider and can cost up to $1,000 without insurance (https://www.singlecare.com/prescription/rapivab). Diarrhea is the most common side effect in adults.
Relenza, the final recommended option, is inhaled as a powder using an inhaler device, twice daily for five days. It’s approved for treating flu in those aged 7 and older and preventing it in those 5 and older. Without insurance, it can cost up to $90 (https://www.goodrx.com/relenza?c). Side effects include allergic reactions, dizziness, and nasal irritation, and it’s not recommended for people with breathing issues like asthma.
Here’s the big question: With Xofluza’s rising popularity, should it replace Tamiflu as the go-to flu treatment? Dr. Brown prefers it for her patients due to its convenience and fewer side effects, but availability and cost remain barriers. Plus, the risk of resistance can’t be ignored. Dr. Schaffner points out that while resistance is rare, it’s a valid concern, especially for younger children. Dr. Tim Uyeki from the CDC adds that resistance is more common in kids and can lead to longer symptom duration, though transmission of resistant viruses remains rare.
For hospitalized patients or those with severe illness, Tamiflu is still the preferred choice. Xofluza isn’t recommended for pregnant or breastfeeding women, severely immunosuppressed individuals, or hospitalized patients due to limited data. However, it shines in cases of influenza B, where it’s more effective than Tamiflu.
So, what’s the takeaway? While Tamiflu remains a reliable option, Xofluza and other alternatives are worth considering—but only after weighing the pros and cons. What do you think? Is Xofluza’s convenience worth the risk of resistance, or should Tamiflu remain the gold standard? Let us know in the comments!
